Andersons pediatric cardiology 1666
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (60.39 KB, 3 trang )
33.HofmanN,TanHL,AldersM,etal.Yieldof
molecularandclinicaltestingforarrhythmia
syndromes:reportof15years’experience.
Circulation.2013;128(14):1513–1521.
34.ColanSD,LipshultzSE,LoweAM,etal.
Epidemiologyandcause-specificoutcomeof
hypertrophiccardiomyopathyinchildren:
findingsfromthepediatriccardiomyopathy
registry.Circulation.2007;115(6):773–781.
35.NugentAW,DaubeneyPE,ChondrosP,etal.
Clinicalfeaturesandoutcomesofchildhood
hypertrophiccardiomyopathy:resultsfroma
nationalpopulation-basedstudy.Circulation.
2005;112(9):1332–1338.
36.MaronBJ,RowinEJ,CaseySA,etal.
Hypertrophiccardiomyopathyinchildren,
Adolescents,andyoungadultsassociatedwith
lowcardiovascularmortalitywithcontemporary
managementstrategies.Circulation.
2016;133(1):62–73.
37.LipshultzSE,OravEJ,WilkinsonJD,etal.Risk
stratificationatdiagnosisforchildrenwith
hypertrophiccardiomyopathy:ananalysisof
datafromthepediatriccardiomyopathyregistry.
Lancet.2013;382(9908):1889–1897.
38.HarrisKM,SpiritoP,MaronMS,etal.
Prevalence,clinicalprofile,andsignificanceof
leftventricularremodelingintheend-stage
phaseofhypertrophiccardiomyopathy.
Circulation.2006;114(3):216–225.
39.MaronBJ,TajikAJ,RuttenbergHD,etal.
Hypertrophiccardiomyopathyininfants:clinical
featuresandnaturalhistory.Circulation.
1982;65(1):7–17.
40.Ostman-SmithI,WettrellG,KeetonB,etal.
Echocardiographicandelectrocardiographic
identificationofthosechildrenwith
hypertrophiccardiomyopathywhoshouldbe
consideredathigh-riskofdyingsuddenly.
CardiolYoung.2005;15(6):632–642.
41.OlivottoI,CecchiF,CaseySA,etal.Impactof
atrialfibrillationontheclinicalcourseof
hypertrophiccardiomyopathy.Circulation.
2001;104(21):2517–2524.
42.SiontisKC,GeskeJB,OngK,etal.Atrial
fibrillationinhypertrophiccardiomyopathy:
prevalence,clinicalcorrelations,andmortalityin
alargehigh-riskpopulation.JAmHeartAssoc.
2014;3(3):e001002.
43.MaronBJ,OlivottoI,BelloneP,etal.Clinical
profileofstrokein900patientswith
hypertrophiccardiomyopathy.JAmColl
Cardiol.2002;39(2):301–307.
44.CecchiF,OlivottoI,GistriR,etal.Coronary
microvasculardysfunctionandprognosisin
hypertrophiccardiomyopathy.NEnglJMed.
2003;349(11):1027–1035.
45.OlivottoI,CecchiF,GistriR,etal.Relevanceof
coronarymicrovascularflowimpairmentto
long-termremodelingandsystolicdysfunction
inhypertrophiccardiomyopathy.JAmColl
Cardiol.2006;47(5):1043–1048.
46.OlivottoI,GirolamiF,SciagraR,etal.
Microvascularfunctionisselectivelyimpairedin
patientswithhypertrophiccardiomyopathyand
sarcomeremyofilamentgenemutations.JAm
CollCardiol.2011;58(8):839–848.
47.FrankS,BraunwaldE.Idiopathichypertrophic
subaorticstenosis.Clinicalanalysisof126
patientswithemphasisonthenaturalhistory.
Circulation.1968;37(5):759–788.
48.HardarsonT,DelaCalzadaCS,CurielR,
GoodwinJF.Prognosisandmortalityof
hypertrophicobstructivecardiomyopathy.
Lancet.1973;2(7844):1462–1467.
49.McKennaW,DeanfieldJ,FaruquiA,etal.
Prognosisinhypertrophiccardiomyopathy:role
ofageandclinical,electrocardiographicand
hemodynamicfeatures.AmJCardiol.
1981;47(3):532–538.
50.SpiritoP,ChiarellaF,CarratinoL,etal.Clinical
